
Exploring how empathetic, patient-centred communication can make planned treatment breaks easier to discuss as part of cancer care.

Following ASCO® 2026, Inizio's experts have shared their perspectives across three thought leadership articles, each exploring a different aspect of what this year's congress revealed for pharmaceutical organisations. Together, they...

Key insights from ASCO® 2026, including oncology trends, scientific highlights, and strategies for smarter congress engagement.

The companies plan to research and develop 12 new cancer treatments

Over 240 million people worldwide live with chronic hepatitis B

The new three-year agreement builds on an existing two-year relationship

The treatment is currently being evaluated in a phase 1/2 multicentre clinical study

The acquisition builds on Gilead’s oncology pipeline, focused on addressing areas of high unmet need

PH has a five‑year survival rate of only around 50% and affects up to 82 million people worldwide

RSV affects approximately 64 million people around the world each year

The financing includes new investors Pfizer Ventures and Apricot Capital, bringing the total capital raised to $100m

Symptoms of COPD include breathlessness, persistent cough and frequent chest infections